XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.3

Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Derivative Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Derivative [Line Items]
Total noncurrent derivative assets	$ 9,351	$ 10,583
Primrose mRNA
Derivative [Line Items]
Total noncurrent derivative assets	0	3,451
Partner Programs | Agenus Bot/Bal
Derivative [Line Items]
Total noncurrent derivative assets	0	6,326
Agenus Warrant | Agenus Bot/Bal
Derivative [Line Items]
Total noncurrent derivative assets	1,282	806
Castle Creek Warrant
Derivative [Line Items]
Total noncurrent derivative assets	5,242	0
Orchestra Warrant
Derivative [Line Items]
Total noncurrent derivative assets	2,112	0
Arecor Warrant
Derivative [Line Items]
Total noncurrent derivative assets	$ 715	$ 0

X

- Definition

Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483444/210-20-55-10

+ Details

Name:	us-gaap_DerivativeAssetsNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 25
-Paragraph 6A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480682/815-20-25-6A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

+ Details

Name:	us-gaap_DerivativeLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	srt_CounterpartyNameAxis=lgnd_PrimroseBioMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=lgnd_AgenusInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=lgnd_CastleCreekWarrantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=lgnd_OrchestraWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_DerivativeInstrumentRiskAxis=lgnd_ArecorWarrantMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: